TRIUMPH-Outcomes

a Phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of retatrutide on the incidence of major adverse cardiovascular events and the decline in kidney function in participants with Body Mass Index ≥ 27kg/m² and atherosclerotic cardiovascular disease and/or chronic kidney disease